81 related articles for article (PubMed ID: 9137528)
1. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.
Hempel G; Krümpelmann S; May-Manke A; Hohenlöchter B; Blaschke G; Jürgens H; Boos J
Cancer Chemother Pharmacol; 1997; 40(1):45-50. PubMed ID: 9137528
[TBL] [Abstract][Full Text] [Related]
2. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
3. New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
[TBL] [Abstract][Full Text] [Related]
4. Trofosfamide in patients with pancreatic cancer.
Schmidt-Sandte W; Dageförde J; Klapdor R; Wagner T; Wiedemann GJ
Anticancer Res; 1999; 19(4A):2485-7. PubMed ID: 10470179
[TBL] [Abstract][Full Text] [Related]
5. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
9. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
Williams ML; Wainer IW; Granvil CP; Gehrcke B; Bernstein ML; Ducharme MP
Chirality; 1999; 11(4):301-8. PubMed ID: 10224657
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
12. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the urinary excretion of ifosfamide and its N-dechloroethylated metabolites in children using 31P-NMR spectroscopy.
Misiura K; Zubowska M; Zielińska E
Arzneimittelforschung; 2003; 53(5):372-7. PubMed ID: 12854365
[TBL] [Abstract][Full Text] [Related]
14. [Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].
Norpoth K; Müller G; Raidt H
Arzneimittelforschung; 1976; 26(7):1376-7. PubMed ID: 1036928
[TBL] [Abstract][Full Text] [Related]
15. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.
Wagner A; Hempel G; Boos J
Anticancer Drugs; 1997 Jun; 8(5):419-31. PubMed ID: 9215603
[TBL] [Abstract][Full Text] [Related]
16. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.
McCune JS; Salinger DH; Vicini P; Oglesby C; Blough DK; Park JR
J Clin Pharmacol; 2009 Jan; 49(1):88-102. PubMed ID: 18927240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
